> Detailanzeige

Arase, Yasuji; Kawamura, Yusuke; Seko, Yuya; Kobayashi, Mariko; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Akuta, Norio; Kobayashi, Masahiro; Sezaki, Hitomi; Saito, Satoshi; Hosaka, Tetsuya; Ikeda, Kenji; Kumada, Hiromitsu; Ohmoto‐Sekine, Yuki; Hsieh, Shiun Dong; Amakawa, Kazuhisa; Ogawa, Kyoko; Matsumoto, Naoki; Iwao, Akiko; Tsuji, Hiroshi; Hara, Shigeko; Mori, Yasumichi; Okubo, Minoru; Sone, Hirohito;

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease
  • Beteiligte: Arase, Yasuji; Kawamura, Yusuke; Seko, Yuya; Kobayashi, Mariko; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Akuta, Norio; Kobayashi, Masahiro; Sezaki, Hitomi; Saito, Satoshi; Hosaka, Tetsuya; Ikeda, Kenji; Kumada, Hiromitsu; Ohmoto‐Sekine, Yuki; Hsieh, Shiun Dong; Amakawa, Kazuhisa; Ogawa, Kyoko; Matsumoto, Naoki; Iwao, Akiko; Tsuji, Hiroshi; Hara, Shigeko; Mori, Yasumichi; Okubo, Minoru; Sone, Hirohito;
  • Erschienen: Wiley, 2013
  • Erschienen in: Hepatology Research
  • Sprache: Englisch
  • DOI: 10.1111/hepr.12077
  • ISSN: 1386-6346; 1872-034X
  • Schlagwörter: Infectious Diseases ; Hepatology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Aim</jats:title><jats:p>The aim of this case–control study was to assess the efficacy and safety of dipeptidyl peptidase‐4 inhibitor (sitagliptin) for type 2 diabetes mellitus (<jats:styled-content style="fixed-case">T2DM</jats:styled-content>) with non‐alcoholic fatty liver disease (<jats:styled-content style="fixed-case">NAFLD</jats:styled-content>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Twenty <jats:styled-content style="fixed-case">NAFLD</jats:styled-content> patients with <jats:styled-content style="fixed-case">T2DM</jats:styled-content> treated by sitagliptin were retrospectively enrolled as the sitagliptin group. These patients were given sitagliptin between <jats:styled-content style="fixed-case">J</jats:styled-content>anuary 2010 and <jats:styled-content style="fixed-case">J</jats:styled-content>uly 2011. Another 20 <jats:styled-content style="fixed-case">NAFLD</jats:styled-content> patients with <jats:styled-content style="fixed-case">T2DM</jats:styled-content> treated only with diet and exercise for 48 weeks were selected as the control group. Serum levels of fasting plasma glucose (<jats:styled-content style="fixed-case">FPG</jats:styled-content>), hemoglobin <jats:styled-content style="fixed-case">A1C</jats:styled-content> (<jats:styled-content style="fixed-case">HbA1c</jats:styled-content>), aspartate aminotransferase (<jats:styled-content style="fixed-case">AST</jats:styled-content>) and alanine aminotransferase (<jats:styled-content style="fixed-case">ALT</jats:styled-content>) were measured before and 12, 24, 36 and 48 weeks after the initiation of treatment.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In the sitagliptin group, average <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> levels decreased approximately 0.7% at 48 weeks after the initiation of sitagliptin. Next, average <jats:styled-content style="fixed-case">FPG</jats:styled-content> levels decreased approximately 15 mg/dL at 48 weeks after the initiation of sitagliptin. The serum levels of <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> and <jats:styled-content style="fixed-case">FPG</jats:styled-content> in the sitagliptin group decreased with statistical significance compared to those in the control group (<jats:italic>P</jats:italic> &lt; 0.05). All the patients could take sitagliptin of 50 mg/day without reduction necessitated by sitagliptin‐related side‐effects. There were no significant changes of average <jats:styled-content style="fixed-case">AST</jats:styled-content> and <jats:styled-content style="fixed-case">ALT</jats:styled-content> levels during follow up of 48 weeks in both sitagliptin and control groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our results indicate sitagliptin is effective and safe for the treatment of <jats:styled-content style="fixed-case">T2DM</jats:styled-content> complicated with <jats:styled-content style="fixed-case">NAFLD</jats:styled-content>.</jats:p></jats:sec>